Other agents broadly tested in ALL models that have led to clinical trials include immunotherapies such as chimeric antigen receptor (CAR) T-cells and monoclonal antibodies targeting CD19 and CD22 (discussed below), small molecule inhibitors targeting NOTCH, CDK4/6, PI3K/Akt/mTOR, JAK/STAT, and mitogen-activated protein kinase (MAPK), and cytotoxic chemotherapeutics32,45,47–49,93,94. This evidence concerns the gene SOAT1 and acute lymphoblastic leukemia.